| Literature DB >> 25356373 |
Thomas Rose1, Gilbert Verbeken2, Daniel De Vos2, Maya Merabishvili3, Mario Vaneechoutte4, Rob Lavigne5, Serge Jennes1, Martin Zizi6, Jean-Paul Pirnay1.
Abstract
Antibiotic resistance has become a major public health problem and the antibiotics pipeline is running dry. Bacteriophages (phages) may offer an 'innovative' means of infection treatment, which can be combined or alternated with antibiotic therapy and may enhance our abilities to treat bacterial infections successfully. Today, in the Queen Astrid Military Hospital, phage therapy is increasingly considered as part of a salvage therapy for patients in therapeutic dead end, particularly those with multidrug resistant infections. We describe the application of a well-defined and quality controlled phage cocktail, active against Pseudomonas aeruginosa and Staphylococcus aureus, on colonized burn wounds within a modest clinical trial (nine patients, 10 applications), which was approved by a leading Belgian Medical Ethical Committee. No adverse events, clinical abnormalities or changes in laboratory test results that could be related to the application of phages were observed. Unfortunately, this very prudent 'clinical trial' did not allow for an adequate evaluation of the efficacy of the phage cocktail. Nevertheless, this first 'baby step' revealed several pitfalls and lessons for future experimental phage therapy and helped overcome the psychological hurdles that existed to the use of viruses in the treatment of patients in our burn unit.Entities:
Keywords: Phage therapy; Pseudomonas aeruginosa; Staphylococcus aureus; antibiotic resistance; burn wound; infection
Year: 2014 PMID: 25356373 PMCID: PMC4212884
Source DB: PubMed Journal: Int J Burns Trauma ISSN: 2160-2026